Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients

Autor:	Catherina J. M. Koning, Linda Mulder, Daisy Jonkers, Samefko Ludidi, Ad A.M. Masclee, José M. Conchillo, Joanna W. Kruimel, I. B. van der Vaart
Přispěvatelé:	Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Gut-liver homeostasis
Jazyk:	angličtina
Rok vydání:	2014
Předmět:	Adult Male medicine.medical_specialty Physiology Placebo Gastroenterology law.invention Irritable Bowel Syndrome Probiotic Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans Irritable bowel syndrome Endocrine and Autonomic Systems business.industry Probiotics Visceral pain Visceral Pain Middle Aged Rome iii medicine.disease Barostat Pathophysiology Surgery Treatment Outcome Hyperalgesia Female medicine.symptom business
Zdroj:	Neurogastroenterology and Motility, 26(5), 705-714. Wiley
ISSN:	1350-1925
DOI:	10.1111/nmo.12320
Popis:	BACKGROUND: Irritable bowel syndrome (IBS) is characterized by heterogeneous pathophysiology and low response to treatment. Up to 60% of IBS patients suffers from visceral hypersensitivity, which is associated with symptom severity and underlying pathophysiological mechanisms. Recently, positive effects of probiotics in IBS have been reported, but overall the response was modest. We performed a study in IBS patients, characterized by visceral hypersensitivity measured with the rectal barostat, aiming to assess the effect of 6 weeks of multispecies probiotic mix on visceral pain perception.METHODS: We conducted a randomized, placebo-controlled, double-blind trial in forty Rome III IBS patients with visceral hypersensitivity. Prior to intake, patients kept a 2-week symptom diary and underwent a rectal barostat measurement. When hypersensitivity was confirmed, participation was allowed and patients received a multispecies probiotic with in vitro proven potential beneficial effects on mechanisms contributing to visceral hypersensitivity (six different probiotic strains; 10(9) cfu/g), or a placebo product of one sachet (5 g) per day for 6 weeks. At the end of the intervention period, visceroperception and symptoms were reassessed.KEY RESULTS: Thirty-five patients completed the trial. The percentage of patients with visceral hypersensitivity decreased significantly in the probiotic and placebo group (76.5% and 71.4%, respectively; N.S. between groups). Improvement in pain scores and mean symptom score did not differ between the probiotic and placebo group.CONCLUSIONS & INFERENCES: In this placebo-controlled trial in IBS patients with visceral hypersensitivity, no significant effect of a multispecies probiotic on viscerperception was observed. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT00702026).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f68a9f8dedf1b1093868ac005dd43d https://doi.org/10.1111/nmo.12320 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.